Compare EXYN & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXYN | CLRB |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 24.5M |
| IPO Year | 2026 | 2008 |
| Metric | EXYN | CLRB |
|---|---|---|
| Price | $2.34 | $1.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 77.4K | 54.4K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $1.80 |
| 52 Week High | $6.98 | $6.52 |
| Indicator | EXYN | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 37.39 | 25.74 |
| Support Level | $1.58 | N/A |
| Resistance Level | $2.86 | $2.70 |
| Average True Range (ATR) | 0.21 | 0.13 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 9.09 | 14.54 |
Exyn Technologies Inc is a pioneer in fully adaptive, cognitive mission-level autonomous robotics and artificial intelligence, delivering solutions that enable safe, efficient, and scalable autonomy in complex, GPS-denied environments. Its mission is to deliver world-class autonomous robots to data-hungry industries, unlocking new insights that drive smarter decisions. The group is leveraging proprietary Level 4B autonomy software and cutting-edge aerial and ground robotic systems. It empowers industries, including mining, construction, critical infrastructure, and defense, with real-time 3D mapping, data analytics, and autonomous navigation. Its software and hardware include ExynAI, ExynAI SDK, ExynView, Nexys, Accessories, and Platforms.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.